Targeting Inflammation Using Salsalate in CardioVascular Disease
NCT ID: NCT00624923
Last Updated: 2019-05-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
340 participants
INTERVENTIONAL
2008-09-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the study is to compare the effect of salsalate or placebo on sub-acute inflammation and coronary plaque, in people with cardiovascular disease. Participants are randomized to active intervention (salsalate) or placebo interventions for a period of 30 months. The primary endpoint is change in plaque volume in the coronary arteries assessed by MDCTA from baseline to 30 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammation and Vascular Function in Atherosclerosis
NCT00760019
Targeting Inflammation to Treat Cardiovascular Aging
NCT01775865
Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease
NCT00715169
Study Effect of VIA-2291 on Vascular Inflammation
NCT00358826
The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
NCT01763996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To determine whether targeting inflammation using salsalate compared with placebo reduces progression of noncalcified coronary artery plaque.
DESIGN, SETTING, AND PARTICIPANTS:
In the Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) trial participants were randomly assigned to 30 months of salsalate or placebo in addition to standard, guideline-based therapies. Randomization was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease.
INTERVENTIONS:
Salsalate (3.5 g/d) or placebo orally over 30 months.
MAIN OUTCOMES AND MEASURES:
The primary outcome was progression of noncalcified coronary artery plaque assessed by multidetector computed tomographic angiography. Secondary outcomes were other measures of safety and efficacy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1- Active Pharmacologic
Salsalate
Salsalate
Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
2- Placebo
Placebo
Placebo
Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Salsalate
Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
Placebo
Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* previous myocardial infarction (≥6 months ago), or
* previous coronary bypass surgery (\> 12 months ago), or
* stable angina, or
* significant non-calcified plaque in at least one coronary artery, or
* abnormal exercise tolerance test or
* an area of reversible ischemia on nuclear imaging study or pharmacologic stress, with subsequent revascularization, or angioplasty, or
* abnormal exercise treadmill stress test with or without nuclear imaging or echocardiography with the following exclusions:
Exclusions based on nuclear imaging:
1. Transient cavity dilation
2. More than one vascular territory involved with reversible defect (multiple defects)
3. Reversible defects involving the anterior wall, septum or apex (LAD territory)
Exclusions based on echocardiography imaging:
1. More than one vascular territory involved with inducible wall motion abnormalities (multiple defects)
2. Inducible wall motion abnormalities involving the anterior wall, septum or apex (LAD territory)
Subjects should be at list 6 months after a myocardial infarction and/or revascularization procedure to be eligible.
In addition, subjects must be:
1. aged 21- 75 years inclusive,
2. BMI ≥ 27 kg/m2 and ≤ 35 kg/m2 if female and ≤ 40 kg/m2 if male (a BMI ≥24.5 for subjects from Asian origin)
3. on a stable dose of an HMG CoA reductase inhibitor (statin) for 1 month at screening or unable to tolerate a statin,
4. have normal renal function, (note estimated creatinine clearance calculated using Cockcroft-Gault (CG) equation ≥60 at screening \[eCrCLCG (ml/min) = \[(140 - age) x weight (kg)\]/\[SCr(mg/dl) x 72\] x \[0.85 if female\],
5. have liver function (ALT, AST) \< 3 times upper limits of normal),
6. normal thyroid function (on stable dose replacement therapy is acceptable),
7. if women are of child bearing potential they must have a pregnancy test prior to the CT angio and use contraception for the remainder of the study
8. patients with T2D must have a fasting glucose of ≤ 200 mg/dl at screening and cannot be treated with thiazolidinedione class agents or insulin or Extendin-4 (Byetta) therapy.
Subjects must be willing to have at least three visits at the Beth Israel-Deaconess Medical Center/Joslin Diabetes Center with a baseline and a 30-month follow-up series of imaging studies including CT angiography of the coronary arteries and imaging of the aorta, abdominal adiposity and liver, and interim visit at 1 year.
Exclusion Criteria
2. significant obstructive disease (≥ 70%) in left main coronary artery, ostial LAD or three-vessel disease by MDCTA
3. Significant heart failure (NYHA class III and IV)
4. Current atrial fibrillation or Wolf-Parkinson-White (WPW) syndrome
5. Allergy to beta-blocker in subjects with resting heart rate \> 65 bpm
6. Systolic blood pressure \> 160 mm Hg
7. Diastolic BP \> 100 mm Hg
8. Persons with allergies to contrast material
9. History of asthma if unable to tolerate beta blocker
10. Allergy to iodinated contrast material or shellfish
11. Allergy to nitroglycerin
12. BMI \> 35 kg/m2 if female and \> 40 kg/m2 if male
13. Body weight \> 350 lbs
14. Use of drugs for weight loss \[e.g. Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the counter medications\] within three months of screening
15. Surgery within 30 days of screening
16. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)
17. Poor mental function or history of dementia/ Alzheimer's Disease or on medications used for treatment of dementia \[e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)\] or any other reason to expect patient difficulty in complying with the requirements of the study
18. Medicine for erectile dysfunction within 72 hours prior to MDCTA
19. History of significant chronic rheumatologic or other chronic inflammatory disease (including foot ulcers)
20. Prior hemorrhagic stroke
21. persons with known aspirin allergy
22. Use of continuous oral corticosteroid treatment (more than 2 weeks), or patients requiring corticosteroids within 3 months
23. Anti-diabetic medication including thiazolidinedione (pioglitazone or rosiglitazone), or insulin or Extendin-4 (Byetta)
24. History of peptic ulcer or gastritis within 5 years
25. Positive stool guaiac
26. Hemoglobin 2 standard deviations below normal
27. Low platelet count (2 standard deviations below normal)
28. Known bleeding disorder
29. Coumadin (warfarin compounds)
30. History of type 1 diabetes and/or history of ketoacidosis
31. Daily use of NSAIDS (including salsalate) for arthritis
32. History of malignancy, except subjects who have been disease-free for greater than 5 years, or whose only malignancy has been basal or squamous cell skin carcinoma
33. History of drug or alcohol abuse, or current weekly alcohol consumption \>14 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)
34. Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric agents
35. Chronic tinnitus.
21 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beth Israel Deaconess Medical Center
OTHER
Tufts Medical Center
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Joslin Diabetes Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francine Welty, MD
Role: STUDY_DIRECTOR
Beth Israel Deaconess Medical Center
Allison B. Goldfine, MD
Role: PRINCIPAL_INVESTIGATOR
Joslin Diabetes Center
Ernest Schaefer, MD
Role: PRINCIPAL_INVESTIGATOR
Tufts Medical Center
Melvin Clouse, MD
Role: PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center
Steven E. Shoelson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Joslin Diabetes Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seacoast Cardiology
York Village, Maine, United States
Joslin Diabetes Center
Boston, Massachusetts, United States
Heart Center of Metrowest
Framingham, Massachusetts, United States
South Shore Internal Medicine
Milton, Massachusetts, United States
Newton-Wellesley Cardiology
Newton, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. doi: 10.1172/JCI29069.
Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. doi: 10.2337/dc07-1338. Epub 2007 Oct 24.
Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.
Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.
Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.
Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE, Reaven PD. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013 Apr;56(4):714-23. doi: 10.1007/s00125-012-2819-3. Epub 2013 Jan 31.
Avadhani R, Fowler K, Barbato C, Thomas S, Wong W, Paul C, Aksakal M, Hauser TH, Weinger K, Goldfine AB. Glycemia and cognitive function in metabolic syndrome and coronary heart disease. Am J Med. 2015 Jan;128(1):46-55. doi: 10.1016/j.amjmed.2014.08.025. Epub 2014 Sep 16.
Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017 Jan 3;127(1):83-93. doi: 10.1172/JCI88884. Epub 2017 Jan 3.
Ridker PM. Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. JAMA Cardiol. 2016 Jul 1;1(4):423-4. doi: 10.1001/jamacardio.2016.0604. No abstract available.
Hauser TH, Salastekar N, Schaefer EJ, Desai T, Goldfine HL, Fowler KM, Weber GM, Welty F, Clouse M, Shoelson SE, Goldfine AB; Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) Study Team. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. JAMA Cardiol. 2016 Jul 1;1(4):413-23. doi: 10.1001/jamacardio.2016.0605.
Day EA, Ford RJ, Smith BK, Houde VP, Stypa S, Rehal S, Lhotak S, Kemp BE, Trigatti BL, Werstuck GH, Austin RC, Fullerton MD, Steinberg GR. Salsalate reduces atherosclerosis through AMPKbeta1 in mice. Mol Metab. 2021 Nov;53:101321. doi: 10.1016/j.molmet.2021.101321. Epub 2021 Aug 21.
Related Links
Access external resources that provide additional context or updates about the study.
Home page for Joslin Diabetes Center, Boston, MA.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCI: 2006-P-00175
Identifier Type: OTHER
Identifier Source: secondary_id
CHS: 06-13
Identifier Type: OTHER
Identifier Source: secondary_id
CHS 06-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.